MYCN and neuroblastoma: In addition, MYCN amplification status is a robust prognostic marker of outcome, but with the intensification of chemoradiotherapy, recent high-risk neuroblastoma trials showed no impact on outcome for patients whose tumors harbor MYCN amplification [27,28], unlike legacy high-risk trials in the past [29].